Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin)

Synonyms: IL17MS3086, ALX-0761, M1095

Catalog No.A4006 Purity:≥99%

Sonelokimab is a humanized trivalent nanobody consisting of monovalent camelid-derived nanobodies that target human interleukin (IL)-17A, IL-17F, and human serum albumin. It exhibits clinical efficacy and dose-dependent modulation of psoriasis-associated genes in patients with plaque-type psoriasis. MW: 40.93 KD.

Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin)

Purity & Quality Control

≥99

Choose Selective Interleukins Inhibitors

Name	Citation	IL-6	IL-1	IL-8	IL-12	IL-10	IL-13	IL-2	Others
SKF-86002	0		++
JTE-607 Dihydrochloride	0	+++	+++	+++		+++			TNF-alpha
A-740003	2		++						rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate	3				++++				PIKfyve
MD2-TLR4-IN-1	0	++							TLR4,TNF-α
Danirixin (GSK1325756)	2			++					CXCR2
Resatorvid (TAK-242)	59	++++							TLR4,NO,TNF-α
Apilimod	15				++++				PIKfyve
LMT-28	0	✔
Atractylodin	0	✔							NAAA
Triolein	0	✔							ROS,MMP-1
Ac-YVAD-cmk	4		✔
Diethyl phosphate	0	✔
RCM-1	3						✔		STAT6,FOXM1,β-catenin
Stylopine	0		✔						COX-2,TNF-α,NO
Myrislignan	1	✔							NF-κB,COX-2,iNOS
NE 52-QQ57	1		✔						iNOS,TNF-α,PGE2
PKR-IN-C16	6		✔						PKR
(3R,8S)-Falcarindiol	3	✔							STAT,ERK,JNK
Gardenoside	0		✔						P2X7 Receptor,P2X3 receptor,NF-κB
T-5224	20		✔						c-Jun,c-Fos/AP-1,Adamts-5
IQ 3	1	✔							TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base)	0	✔							TNFα,MCP-1/CCL2,NOX2
AUDA	0		✔						p38,Smad3,TGF-β
SAR-20347	1				✔				IFN-α,TYK2,JAK1
SU 5201	0							✔
Madecassic acid	1		✔						TNF-α,COX-2,iNOS
Homoplantaginin	1	✔							NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone	1	✔							NF-κB,ERK1/2,iNOS
Forsythoside B	0	✔							NF-κB,TNF-alpha,IκB
Mulberroside A	0		✔						NF-κB,Caspase-1,NALP3
Chelidonic acid	0	✔							glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin	0	✔							MPO
Muscone	3		✔						TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101)	13		✔
Methylthiouracil	0	✔							ERK1/2,NF-κB,TNF-α

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Sonelokimab is a humanized trivalent nanobody consisting of monovalent camelid-derived nanobodies that target human interleukin (IL)-17A, IL-17F, and human serum albumin. It exhibits clinical efficacy and dose-dependent modulation of psoriasis-associated genes in patients with plaque-type psoriasis. MW: 40.93 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1414386-05-2
Source	CHO
Storage (From the date of receipt)	-80℃(avoid freeze-thaw cycles)

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.

Tags: buy Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin) | Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin) supplier | purchase Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin) | Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin) cost | Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin) manufacturer | order Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin) | Sonelokimab (Anti-IL-17 & IL-17F & Serum Albumin) distributor